Perrigo and Hikma subsidiary West-Ward Pharmaceuticals have launched an OTC fluticasone propionate nasal spray, a generic version of Flonase, in the US after receiving approval for the product from the FDA, the companies said. The nasal spray will be marketed under store brand names. Flonase was approved for over-the-counter sales in the US in 2014.
Hikma completed its acquisition of Roxane Laboratories, which manufactures fluticasone propionate nasal spray, from Boehringer Ingelheim in February 2016, and Roxane is now part of West-Ward.
West-Ward Pharmaceuticals CEO Michael Raya said, “We are very pleased to be working with Perrigo to improve access to this important product for consumers interested in purchasing fluticasone propionate nasal spray over-the-counter.”
Perrigo CEO John T. Hendrickson commented, “This product approval and launch demonstrates the power of Perrigo’s OTC platform. Our team has made significant efforts to bring this important product to our customers and consumers in the US. Important product launches like the store brand switch of fluticasone are what drive the Perrigo advantage by providing our consumers with high quality, value alternatives in important treatment categories.”
Read the Perrigo press release.
Read the Hikma press release.
